论文部分内容阅读
目的:探讨瑞舒伐他汀钙治疗冠心病合并肾功能不全患者的临床疗效。方法:分析2010年1月-2013年6月在某院接受治疗的老年冠心病合并肾功能不全患者的临床资料,根据随机数字法分为观察组(57例):在原有冠心病、肾功能不全常规药物治疗基础上联合使用瑞舒伐他汀钙长期治疗;对照组(61例):使用常规药物治疗,未曾使用他汀类药物;分别于治疗前和治疗后6个月测定血清尿素氮、肌酐,血浆肾素、血管紧张素Ⅱ及醛固酮的水平,以及24 h尿蛋白。结果:与对照组相比,治疗后6个月观察组患者的血清肌酐和尿素氮水平,以及尿蛋白含量显著降低(P<0.05);与对照组相比,观察组患者的超氧化物歧化酶和谷胱甘肽过氧化物酶水平显著增加(P<0.05),血管紧张素Ⅱ水平明显降低(P<0.05),肾素的活性及醛固酮的含量无明显统计学差异(P>0.05)。结论:冠心病合并肾功能不全的患者在常规治疗基础上联合使用瑞舒伐他汀钙治疗可以改善肾功能不全。
Objective: To investigate the clinical efficacy of rosuvastatin calcium in patients with coronary heart disease complicated with renal insufficiency. Methods: The clinical data of elderly patients with coronary heart disease and renal insufficiency treated in a hospital from January 2010 to June 2013 were analyzed. According to the random number method, the patients were divided into observation group (57 cases): in the original coronary heart disease, renal function Long-term treatment with rosuvastatin calcium on the basis of incomplete conventional drug treatment; control group (61 cases): no conventional statins were used in the control group; serum urea nitrogen and creatinine were measured before treatment and 6 months after treatment , Plasma renin, angiotensin II and aldosterone levels, and 24 h urine protein. Results: Compared with the control group, serum creatinine and urea nitrogen levels and urinary protein levels in the observation group were significantly decreased (P <0.05) at 6 months after treatment. Compared with the control group, the levels of serum superoxide dismutase (P <0.05), the level of angiotensin Ⅱ (P <0.05), the activity of renin and the content of aldosterone were not significantly different (P> 0.05) . Conclusion: Coronary heart disease with renal insufficiency in patients with renal failure on the basis of conventional treatment combined with rosuvastatin calcium therapy can improve renal insufficiency.